INTRODUCTION T, Mabe K, Hanawa T, Kamiya S. Urease-positive

INTRODUCTION

Helicobacter pylor is spiral in form with a flagellum, gram-negative,
microaerophilic bacterium in the human gastric mucosa, It is supposed to be the
most common bacterial infection and a leading risk factor for developing
gastric cancer in50% – 75% of the population all over the world also it is
associated with upper gastrointestinal diseases, including peptic ulcer disease
(gastric and duodenal), chronic gastritis, gastric cancer associated lymphoid
tissue lymphoma.( Lee HS. Histopathologic Diagnosis of H. pylori Infection). Helicobacter pylori: Springer;
2016: 119-27. Testing for H. pylori is highly recommended in patients with ; Active
peptic ulcer disease , After resection of early gastric cancer, Dyspepsia
undergoing upper endoscopy ,Gastric MALT lymphoma, History of peptic ulcer
disease, Idiopathic thrombocytopenic purpura (ITP),Unexplained iron deficiency
anemia, Family history of gastric cancer , Hyperplastic gastric polyps and Lymphocytic
gastritis. Transmission could be via feco-oral or mouth to mouth. Not all
infected individuals with H. pylori have the same symptoms the reasons due to
variation in the bacterial virulence and host risk factors. 90-95% of patients
with duodenal ulcers and seventy percent 
of gastric ulcers are associated with H. pylori infections. Recently,
reviews and and statistical analysis revealed that extra gastric diseases are
also associated with H. pylori infections, such as unexplained iron deficiency
anemia, idiopathic thrombocytopenic purpura ITP, unexplained vitamin B12
deficiency (megaloblastic anemia) , and the association of CagA -positive HP
strains with ischemic heart diseases IHD . ( Vítor JM, Vale FF.)

We Will Write a Custom Essay Specifically
For You For Only $13.90/page!


order now

 Urea breath test :Urea breath test is considered the
gold standard method of diagnosis in both pre- and post-eradicated cases. It is
non-invasive, simple, highly accurate, but expensive ,  has a sensitivity of 96-100% and specificity
of 100% , also is  the most reliable
method of diagnosing HP infection in pre- and post-eradicated cases (
Osaki T, Mabe K, Hanawa
T, Kamiya S. Urease-positive bacteria in the stomach induce a false-positive
reaction in a urea breath test for diagnosis of Helicobacter pylori )

Stool
antigen test

The stool antigen
test provides accurate and sensitive diagnosis in pre- and post-treatment cases
of H. pylori infections. A 4-8 week post -treatment evaluation has excellent
result but an evaluation 95%.  Moxifloxacin-based  sequential therapy (Rebeprazole
20 mg+ amoxicillin 1 gm bid*7d followed by Rebeprazole 20 mg+ metronidazole 500
mg+ moxifloxacin 400 mg bid*7d)

 Concomitant therapy  four drugs are concomitantly given for 7-14 days. (esomeprazole, 40 mg; amoxicillin 1gm, clarithromycin, 500 mg;
metronidazole, 500 mg) bid*10 days. 7 days of concomitant therapy (pantoprazole, 40 mg; amoxicillin, 1 mg;
clarithromycin, 500 mg; metronidazole, 500 mg bid) . 7- day concomitant therapy (Rebeprazole, amoxicillin, clarithromycin, metronidazole)  . omeprazole, 20 mg; amoxicillin, 1 gm;
clarithromycin, 500 mg; and tinidazole, 500 mg for 14 days concomitant therapy .

 Hybrid therapy:  hybrid therapy of omeprazole, 20
mg, and amoxicillin, 1 gm twice daily for 7 days,followed by omeprazole, 20 mg;
clarithromycin, 500 mg; and tinidazole, 500 mg twice daily for
another 7 days . hybrid therapy of esomeprazole, 40 mg, and amoxicillin, 1 gm, twice daily for 14 days plus
clarithromycin, 500 mg, and metronidazole, 500 mg, twice daily for the final 7
days (Zullo A, et al. Concomitant, sequential, and hybrid therapy for H. pylori
eradication: a pilot study. Clinics and research in hepatology and gastroenterology.)

 Rescue therapy :Rescue triple therapy (ecabet sodium, 2 gm; lansoprazole, 30 mg; amoxicillin,
750 mg bid) for 2 weeks. Rescue quadruple
therapy that is tetracycline-based, RRMB (Rebeprazole, rifabutin, minocycline,
bismuth subcitrate)(Furuta T, Furukawa K, et al. Triple therapy with ecabet
sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H.
pylori infection)  RRMB regimen
can be an option in those who have failed at least 2 previous triple regimens. Rescue quadruple  therapy  (rebeprazole, 
20  mg amoxicillin 1  gm; 
bismuth  subcitrate 220  mg ,furazolidone, 100 mg bid*14 days or
furazolidone, 10mg tid *7 days)

REGIMENS THERAPIES ACCORDING TO THE
RECENT GUIDELINES  (Malfertheiner ,
Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori
infection.)

1st line regimen therapies include; 
in high resistant areas to clarithromycin   we can use Bismuth quadruple
therapy referred to as PBMT PPI + Bismuth + Metronidazole +
Tetracycline or Concomitant quadruple therapy
referred to as PAMC PPI + Amoxicillin + Metronidazole + Clarithromycin
The challenge of Helicobacter pylori resistance to
antibiotics: the comeback of bismuth-based quadruple therapy.).  In areas of low resistance to clarithromycin, The
following are the preferred clarithromycin triple therapy regimens: Clarithromycin
triple therapy (referred to as PAC PPI + Amoxicillin + Clarithromycin or PMC
PPI +Metronidazole + Clarithromycin for 14 days The following are alternatives
in case of failure of at least 2 previous first-line regimens: (Zagari RM,
Romano, Annibale B, et al. Guidelines for the management of Helicobacter pylori
infection)

1.PAM (PPI +
Amoxicillin + Metronidazole) for 14 days 
PPI:  omeprazole 20 mg BID or an
equivalent dose of an alternate PPI , Amoxicillin 1000 mg BID, Metronidazole
500 mg BID

2. Sequential therapy :PPI:  omeprazole 20 mg BID or an equivalent dose of
an alternate PPI for five to seven days, Amoxicillin 1000 mg BID for five to
seven days, Followed by PMC  for five to
seven days (Jung SM, Cheung DY, Kim JI, Kim I,
Seong H. Comparing the Efficacy of Concomitant Therapy with Sequential Therapy
as the First-Line Therapy of Helicobacter pylori Eradication)

3.Hybrid therapy :
PPI:  omeprazole 20 mg BID or an
equivalent dose of an alternate PPI for seven days ,Amoxicillin 1000 mg BID for
seven days Followed by PAMC  for seven
days

4. Levofloxacin triple therapy for ten to
14 days : PPI:  omeprazole 20 mg BID or
an equivalent dose of an alternate PPI, Amoxicillin 1000 mg BID,Levofloxacin
500 mg QD (Yoon H, Kim N, Lee BH, Hwang TJ, Lee DH, Park YS, et
levofloxacin? Containing Triple Therapy as Second?Line Treatment for Helicobacter
pylori Infection: Effect of Treatment Duration and Antibiotic Resistance on the
Eradication Rate )

5. Levofloxacin sequential therapy :PPI:  omeprazole 20 mg to 40 mg BID or an
equivalent dose of an alternate PPI for five to seven days, Amoxicillin 1000 mg
BID for five to seven days, Followed by five to seven days of:PPI:  omeprazole 20 mg to 40 mg BID or an
equivalent dose of an alternate PPI,Amoxicillin 1000 mg BID, Levofloxacin 500
mg QD, Metronidazole 500 mg BID

6.LOAD therapy (Levofloxacin
+ Omeprazole +alinia( nitazoxanide) + Doxycycline) therapy for seven to ten
days. (Basu ,rishnaswamy N, Flynn M. A randomized study
comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple
therapy for the eradication of Helicobacter pylori. The American journal of
gastroenterology)

II. Materials And Methods

 All patients undergoing endoscopy
for whatever reason in the agoza hospital, will be the test subjects of the
pilot . All the biopsy samples from gastric and duedunal lesions will be
gathered altogether in a filter soaked with normal saline and without
application of formalin followed by conventional tissue processing using  hematoxylin
with eosin staining, In addition, Geimsa staining will be applied to confirm
the presence of helicobacter Pylori . Biopsies confirmed positive to
helicobacter pylori infection will be processed for culture and sensitivity

III. Aim of the pilot: to overcome
the problem of Antibiotic resistance and eradication failure , by applying the
culture and sensitivity testing ,before any medical approach will allow to use
the most appropriate eradication regimen from the start .The high rate of clarithromycin resistance  made us prevent  its 
empirical  use  in standard triple anti-H pylori  regimens. resistance  rates 
of  metronidazole  and clarithromycin are significantly
elevating allover wide world followed by levofloxacin. Therefore, the
culture-guided therapy for H. pylori is currently mandatory specifically in
well-known antibiotic resistant countries.

IV. INCLUSION CRITERIA: these
conditions will determine the candidate patients

1.     
Patients with long term
dyspepsia especially those who developed alarming signs as cachexia

2.     
All patients undergoing
endoscopy are not diagnosed or known to be infected with helicobacter pylori

3.     
Patients wheather
received  PPI or antibiotic therapy or
both and the patients whom didn’t take any therapy will be included

4.     
Patients providing full
consent

5.     
Biopsies will be mainly
taken from the antrum of the stomach and the 1st part of duodenum

6.     
Full medical examination
along lab investigations as CBC ,liver and renal function tests

7.     
Age of the patients will
range from late twenties up to early fifties, pediatrics and geriatrics will be
excluded.

REFRENCES

1.   Vítor JM, Vale FF. Alternative therapies for
Helicobacter pylori: Immunology & Medical Microbiology.

2. Choi YJ: Diagnosis of
H. pylori Infection

3.   Helicobacter, Group CC. Gastric cancer and
Helicobacter pylori 2015

4.   Kim SG, Jung HK et al. Guidelines for the
diagnosis and treatment of Helicobacter pylori infection  2017

5.   Tonkic , Mégraud F. Epidemiology and
diagnosis of Helicobacter pylori infection 2008

6.   Hun Van Der Merwe S. World gastroenterology
organisation global guideline of gastrointestinal and liver disease. 2009

7.   Zhang Yang Y, et al. Seroepidemiology of
Helicobacter pylori infection. World journal of gastroenterology

8.   Kato M,  Recent knowledge of the relationship between
Helicobacter pylori and gastric cancer and recent progress of gastroendoscopic
diagnosis and treatment for gastric cancer. Japanese journal of clinical
oncology.

9.   Lee S-Y. Current progress toward eradicating
Helicobacter pylori , differences in the 2013 revised guidelines between China,
Japan, and South Korea. World journal of gastroenterology. 2014

10.Cancer Research UK:
Information resource center 2004.

 11 .Suzuki , Wakai K, et al. Smoking
increases the treatment failure for Helicobacter pylori eradication. The
American journal of medicine. 2006

12. Malfertheiner P,Atherton J, Axon AT, Bazzoli F,
et al. Management of Helicobacter pylori infection—the Maastricht IV/Florence
consensus 2012

13. Ekström AM, Held Nyrén O. Helicobacter pylori
in gastric cancer established by CagA immune-Gastroenterology. 2001

14. Zagari RM, Romano B, et al. Guidelines for the
management of Helicobacter pylori infection in Italy: the III Working Group
Consensus Report 2015

15. Cid TP, Fernández MC, Jones NL. Pathogenesis of
Helicobacter pylori infection. Helicobacter. 2013

16. Machado JC, Yamaoka Y. Pathogenesis of
Helicobacter Pylori infection Helicobacter.2005

17.  Costa AC. Pathogenesis of Helicobacter pylori
infection. Helicobacter 2009                                        

18. Backert S, Clyne M. Pathogenesis of
Helicobacter pylori infection. Helicobacter. 2011

19. Zou QH, Li RQ. Helicobacter pylori in the oral
cavity and gastric mucosa: a meta?analysis. Journal of Oral Pathology & Medicine.
2011

20. Mentis A. Epidemiology and Diagnosis of
Helicobacter pylori infection. Helicobacter. 2015

21. Lario A Ju F, Martinez-Bauer E, accuracy of
three monoclonal stool tests in a large series of untreated Helicobacter pylori
infected patients. Clinical biochemistry.2016

22. Calvet ,Lázaro MJ, Quesada M, et al. Accuracy
of diagnostic tests for Helicobacter pylor. Clinical Infectious Diseases. 2009

23. Vaira D, Gci C. Diagnosis of Helicobacter
pylori infection. Alimentary pharmacology. 2002

24. Ferwana M, Abdulmajeed , Firwana B, Hasan R, et
al. Accuracy of urea breath test in Helicobacter pylori infection: Meta-analysis.
World journal of gastroenterology 2009

25. Osaki T , Urease-positive bacteria in the
stomach induce a false-positive reaction in a urea breath test for diagnosis of
Helicobacter pylori infection. Journal of medical microbiology. 2008

26. Braden B. Diagnosis of Helicobacter pylori
infection. 2012

27. Buharidee . Journal of Diagnostic Pathology.
2016

28. Lee HS. Histopathologic Diagnosis of H. pylori
Infection and Associated Gastric Diseases. 2016

29.Black DD, Casteel HB
et al. Comparison of immunohistochemistry and silver stain for the diagnosis of
pediatric Helicobacter pylori infection in urease-negative gastric biopsy.2001

30. Uchida T al. Immunohistochemical diagnosis of
the cagA?gene genotype of Helicobacter pylori with anti CagA?specific antibody.
Cancer science. 2007

31. Allahverdiyev AM, et al. Isolation and
diagnosis of Helicobacter pylori by a new method: microcapillary culture. World
J Gastroenterology. 2015

32 Sato Y, Hayakawa M,
et al. Detection of Helicobacter pylori (H. pylori) DNA in digestive systems by
real- time PCR, Legal Medicine.2009

33. Kabir S. Detection of Helicobacter pylori DNA
in feces and saliva by polymerase chain reaction: 2004

34. Glocker E, Kist M. Rapid detection of point
mutations in the gyra gene of Helicobacter pylori conferring resistance to
ciprofloxacin. Journal of clinical microbiology. 2004

35. Oleastro M, et al. Real-time PCR assay for
rapid and accurate detection of point mutations conferring resistance to
clarithromycin in Helicobacter pylori. 2003

36. Oleastro M,S, et al. Helicobacter pylori
virulence genotypes in Portuguese adults with gastroduodenal pathology.
European Journal of Clinical Microbiolog 2003

37. Ribeiro ML, Kuipers EJ, clinical isolates of
Helicobacter pylori using PCR-RFLP. Immunology & Medical Microbiology. 2004

38. Chung WC et al. Dual-priming
oligonucleotide-based multiplex PCR using tissue samples from the rapid urease
test kit for the detection of Helicobacter pylori in bleeding peptic ulcers.
Digestive and Liver Disease. 2014

39.Endoscopic Biopsies.
J Med Res Health Sci. 2013

40. Mustapha NA, Nggada
HA, Pindiga UH, Gashau W, Khalil MIA. Endoscopic Findings and The Frequency

of Helicobacter Pylori
Among Dyspeptic Patients in North-Eastern Nigeria. Highland Medical Research
Journal. 2007

41. Pailoor K Naik RCN.
Histopathological diagnosis of gastric biopsies in correlation with endoscopy –
a study in a

tertiary care center.
Adv Lab Med Int. 2013

42. Rosai J In: Rosai
and Ackerman’s surgical pathology. 9th ed. St. Louis: Mosby; 2004.

43.Ahmad MM, Rahman M,
Rumi AK, Islam S, Jinnah F, Morshed MG, Hassan MS, Khan AK, Hasan M. Prevalence
of Helicobacter pylori in asymptomatic population – a pilot serological study Epidemiol
1997

44. Ramakrishna BS.
Helicobacter pylori infection in India: the case against eradication. Indian J
Gastroenterology. 2006

45. Perez-perez GI, Dunn
BE, Echeverria PD . Seroprevalence of Helicobacter pylori infections in
Thailand. 1990

46. Hoang TT,
Bengtsson  . Seroprevalence of
Helicobacter pylori infection in urban vitenam 2007

47.Kumar ,
Histopathological changes in gastric mucosa colonized by H. pylori. Indian Journal
of Pathology and Microbiology. 2006

48.. Dominis M, Dzebro
S, Gasparov S  M. Morphology of gastritis
and Helicobacter pylori. 2002

50. Cancer Research UK:
Information resource center 2004.

51. Rabbani A.
Experience with Endoscopy at Bin Jalawi Hospital K.S.A. 2005

52. Fielding JW.
Outcome of Index Upper Gastrointestinal Endoscopy in Patients Presenting with Dysphagia
in a Tertiary Care Hospital  BMC
Gastroenterology. 2007

53. Kazi J I, Alam SM,
Kazi AM, Endoscopic and Histologic Diagnosis in Upper Gastrointestinal lesions.
JPMA. 1990

54. Bhatty AS, Shaikh
NA, Zahir N, Manzoor H. Histopathologic Spectrum of Upper Gastrointestinal Endoscopies.
Medical Channel. 200